ClinicalTrials.gg

Program

MWN105

A development code. Also written as “MWN105 1”, “MWN105 2” and “MWN105 3”.

Its studies are mostly in Obesity, led by Lepu Medical.

Furthest: phase 2, since Sep 1, 20263 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lepu Medical31 open or runningphase 2since Sep 1, 2026Aug 31, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2026First study: phase 1 study in OverweightFirst studyNCT07801313 · 55 enrolled · China
  2. Sep 1, 2026Phase 2 study in OverweightPhase 2 reachedNCT07804810 · 120 enrolled · China
  3. Sep 1, 2026Phase 1 study in OverweightNCT07803809 · 36 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07804810Overweight · China2CompletedMar 21, 2026120
NCT07803809Overweight · China1RecruitingOct 202636
NCT07801313Overweight · China1CompletedJul 20, 202555

How it is read

Names in the registry

  • “MWN105 1”, 2 entries
  • “MWN105 2”, 2 entries
  • “MWN105 3”, 2 entries
  • “MWN105”, 2 entries

Codes read as this program: MWN105.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.